Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Nivolumab (Opdivo) is now approved to treat advanced renal cell cancer in patients who have already received antiangiogenic therapy.

 

* The drug has the potential to cause serious immune-mediated effects, such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, rash, and encephalitis.